Acute coronary syndromes in patients with atrial fibrillation and heart failure. Could novel oral anticoagulants be the solution of the optimal antithrombotic therapy puzzle?

Maria Boutsikou, Chrysafios Girasis, Emmanouil Petrou, Gregory Pavlides

Research output: Contribution to journalArticle

Abstract

The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.

Original languageEnglish (US)
Pages (from-to)14-20
Number of pages7
JournalCardiovascular and Hematological Agents in Medicinal Chemistry
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Acute Coronary Syndrome
Anticoagulants
Atrial Fibrillation
Heart Failure
Therapeutics
Hemorrhage
Vitamin K
Bibliography

Keywords

  • Acute coronary syndromes
  • Atrial fibrillation and heart failure
  • Novel oral anticoagulants

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7c3daca80f824007ab58cd1640ac720c,
title = "Acute coronary syndromes in patients with atrial fibrillation and heart failure. Could novel oral anticoagulants be the solution of the optimal antithrombotic therapy puzzle?",
abstract = "The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.",
keywords = "Acute coronary syndromes, Atrial fibrillation and heart failure, Novel oral anticoagulants",
author = "Maria Boutsikou and Chrysafios Girasis and Emmanouil Petrou and Gregory Pavlides",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/1871525712666141010151155",
language = "English (US)",
volume = "12",
pages = "14--20",
journal = "Cardiovascular and Hematological Agents in Medicinal Chemistry",
issn = "1871-5257",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Acute coronary syndromes in patients with atrial fibrillation and heart failure. Could novel oral anticoagulants be the solution of the optimal antithrombotic therapy puzzle?

AU - Boutsikou, Maria

AU - Girasis, Chrysafios

AU - Petrou, Emmanouil

AU - Pavlides, Gregory

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.

AB - The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.

KW - Acute coronary syndromes

KW - Atrial fibrillation and heart failure

KW - Novel oral anticoagulants

UR - http://www.scopus.com/inward/record.url?scp=84925389284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925389284&partnerID=8YFLogxK

U2 - 10.2174/1871525712666141010151155

DO - 10.2174/1871525712666141010151155

M3 - Article

C2 - 25308910

AN - SCOPUS:84925389284

VL - 12

SP - 14

EP - 20

JO - Cardiovascular and Hematological Agents in Medicinal Chemistry

JF - Cardiovascular and Hematological Agents in Medicinal Chemistry

SN - 1871-5257

IS - 1

ER -